China Meheco Group Co

China Meheco Group Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of China Meheco Group Co (600056.SS) as of Oct 22, 2026 is 1.17 B CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 1.46 B CNY — a change of -19.31% (lower).

EBITDA

1.17 BCNY

YoY

-19.31%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of China Meheco Group Co is 2025 1.17 B CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of China Meheco Group Co was 2024 1.46 B CNY. It decreases by -19.31% lower compared to the previous year.

The China Meheco Group Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
1.97 B CNY
Jan 1, 2019
1.95 B CNY
Jan 1, 2020
2.05 B CNY
Jan 1, 2021
1.55 B CNY
Jan 1, 2022
1.44 B CNY
Jan 1, 2023
2.01 B CNY
Jan 1, 2024
1.46 B CNY
Jan 1, 2025
1.17 B CNY
The China Meheco Group Co EBITDA history
YEAREBITDAYoY
1.17 BCNY-19.31%
1.46 BCNY-27.45%
2.01 BCNY+39.78%
1.44 BCNY-7.46%
1.55 BCNY-24.21%
2.05 BCNY+5.10%
1.95 BCNY-0.89%
1.97 BCNY-7.18%
2.12 BCNY+39.49%
1.52 BCNY+50.66%
1.01 BCNY+22.38%
823.32 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

China Meheco Group Co Stock analysis

What does China Meheco Group Co do? China Meheco Group Co., Ltd. generates revenue through its Industrial Pharmaceutical segment, which manufactures and distributes chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces. The Commercial Pharmaceutical segment focuses on wholesale and distribution of pharmaceuticals and medical devices. The Trading segment handles international exporting and medical resourcing introduction. The company serves healthcare providers, hospitals, and pharmacies through its wholesale operations, targeting the pharmaceutical and medical device markets in China and internationally. The Industrial Pharmaceutical segment produces chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces for distribution. The Commercial Pharmaceutical segment supplies pharmaceuticals and medical devices to healthcare institutions and retailers. The Trading segment facilitates international exports of pharmaceutical products and introduces medical resources globally, catering to global healthcare markets. China Meheco's revenue streams are derived from the sale of pharmaceutical products across its three segments. The Industrial segment manufactures and sells chemical and traditional Chinese medicine products, while the Commercial segment distributes these products through wholesale channels. The Trading segment earns from exporting pharmaceuticals and managing international medical resource procurement for global clients. China Meheco Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about China Meheco Group Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of China Meheco Group Co is 1.17 B CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of China Meheco Group Co changed from 1.46 B CNY to 1.17 B CNY, representing a -19.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) China Meheco Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s China Meheco Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — China Meheco Group Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — China Meheco Group Co